Halozyme Therapeutics, Inc.
US ˙ NasdaqGS ˙ US40637H1095

SecurityHALO / Halozyme Therapeutics, Inc.
InstitutionSei Investments Co
Latest Disclosed Ownership901,144 shares
Latest Disclosed Value $ 60,646,765
Sei Investments Co reports 95.48% increase in ownership of HALO / Halozyme Therapeutics, Inc.

On February 13, 2026 - Sei Investments Co filed a 13F-HR form disclosing ownership of 901,144 shares of Halozyme Therapeutics, Inc. (US:HALO) valued at $60,646,991 USD as of December 31, 2025. The entity filed a previous 13F-HR on November 13, 2025 disclosing 460,992 shares of Halozyme Therapeutics, Inc.. This represents a change in shares of 95.48% during the quarter. The current value of the position is $62,917,874 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-02-13 2025-12-31 13F HALOZYME THERAPEUTICS COM 40637H109 901,144 440,152 95.48 60,647 79.38 0.0599
2025-11-13 2025-09-30 13F HALOZYME THERAPEUTICS COM 40637H109 460,992 49,614 12.06 33,809 57.99 0.0364
2025-08-14 2025-06-30 13F HALOZYME THERAPEUTICS COM 40637H109 411,378 214,655 109.12 21,399 70.48 0.0248
2025-05-14 2025-03-31 13F/A-1 HALOZYME THERAPEUTICS COM 40637H109 196,723 30,758 18.53 12,553 58.21 0.0162
2025-05-13 2025-03-31 13F HALOZYME THERAPEUTICS COM 40637H109 218,855 52,890 11,488 0.0125
2025-02-11 2024-12-31 13F HALOZYME THERAPEUTICS COM 40637H109 165,965 -169,934 -50.59 7,935 -58.73 0.0102
2024-11-12 2024-09-30 13F HALOZYME THERAPEUTICS COM 40637H109 335,899 11,690 3.61 19,227 13.26 0.0250
2024-08-13 2024-06-30 13F HALOZYME THERAPEUTICS COM 40637H109 324,209 -4,914 -1.49 16,976 26.79 0.0241
2024-05-07 2024-03-31 13F HALOZYME THERAPEUTICS COM 40637H109 329,123 -151,673 -31.55 13,389 -24.66 0.0196
2024-02-14 2023-12-31 13F HALOZYME THERAPEUTICS COM 40637H109 480,796 -47,304 -8.96 17,770 -11.91 0.0285
2023-11-14 2023-09-30 13F HALOZYME THERAPEUTICS COM 40637H109 528,100 134,129 34.05 20,173 41.96 0.0362
2023-08-11 2023-06-30 13F HALOZYME THERAPEUTICS COM 40637H109 393,971 -15,384 -3.76 14,210 -9.10 0.0248
2023-05-12 2023-03-31 13F HALOZYME THERAPEUTICS COM 40637H109 409,355 41,578 11.31 15,633 -25.29 0.0290
2023-02-10 2022-12-31 13F HALOZYME THERAPEUTICS COM 40637H109 367,777 -50,869 -12.15 20,927 26.42 0.0465
2022-11-14 2022-09-30 13F HALOZYME THERAPEUTICS COM 40637H109 418,646 25,629 6.52 16,553 -4.31 0.0369
2022-08-15 2022-06-30 13F HALOZYME THERAPEUTICS COM 40637H109 393,017 -17,154 -4.18 17,299 5.53 0.0374
2022-05-13 2022-03-31 13F HALOZYME THERAPEUTICS COM 40637H109 410,171 -33,482 -7.55 16,393 -8.19 0.0329
2022-02-14 2021-12-31 13F HALOZYME THERAPEUTICS COM 40637H109 443,653 69,515 18.58 17,856 17.27 0.0335
2021-11-12 2021-09-30 13F HALOZYME THERAPEUTICS COM 40637H109 374,138 -14,264 -3.67 15,226 -13.66 0.0319
2021-08-06 2021-06-30 13F HALOZYME THERAPEUTICS COM 40637H109 388,402 -19,709 -4.83 17,635 3.70 0.0391
2021-05-12 2021-03-31 13F HALOZYME THERAPEUTICS COM 40637H109 408,111 100,271 32.57 17,005 29.64 0.0428
2021-02-08 2020-12-31 13F HALOZYME THERAPEUTICS COM 40637H109 307,840 -225,650 -42.30 13,117 -6.31 0.0339
2020-12-04 2020-09-30 13F/A-1 HALOZYME THERAPEUTICS COM 40637H109 533,490 -14,443 -2.64 14,000 -4.53 0.0405
2020-11-06 2020-09-30 13F HALOZYME THERAPEUTICS COM 40637H109 533,505 -14,428 14,000 33,708.8873
2020-08-17 2020-06-30 13F/A-1 HALOZYME THERAPEUTICS COM 40637H109 547,933 48,467 9.70 14,664 63.68 0.0455
2020-08-11 2020-06-30 13F HALOZYME THERAPEUTICS COM 40637H109 122,936 -376,530 2,426 6,580.6541
2020-05-14 2020-03-31 13F HALOZYME THERAPEUTICS COM 40637H109 499,466 406,136 435.16 8,959 442.97 0.0329
2020-02-06 2019-12-31 13F HALOZYME THERAPEUTICS COM 40637H109 93,330 -53,461 -36.42 1,650 -27.54 0.0049
2019-11-12 2019-09-30 13F HALOZYME THERAPEUTICS COM 40637H109 146,791 15,441 11.76 2,277 0.89 0.0058
2019-08-14 2019-06-30 13F HALOZYME THERAPEUTICS COM 40637H109 131,350 -22,245 -14.48 2,257 -8.73 0.0074
2019-05-15 2019-03-31 13F HALOZYME THERAPEUTICS COM 40637H109 153,595 -222,744 -59.19 2,473 -63.83 0.0083
2019-02-13 2018-12-31 13F HALOZYME THERAPEUTICS COM 40637H109 376,339 0 0.00 6,838 0.00 0.0243
2018-11-08 2018-09-30 13F HALOZYME THERAPEUTICS COM 40637H109 376,339 40,715 12.13 6,838 20.77 0.0248
2018-08-03 2018-06-30 13F HALOZYME THERAPEUTICS COM 40637H109 335,624 11,580 3.57 5,662 -10.81 0.0192
2018-05-11 2018-03-31 13F HALOZYME THERAPEUTICS COM 40637H109 324,044 14,987 4.85 6,348 1.39 0.0243
2018-02-08 2017-12-31 13F HALOZYME THERAPEUTICS COM 40637H109 309,057 -13,205 -4.10 6,261 11.84 0.0217
2017-11-06 2017-09-30 13F HALOZYME THERAPEUTICS COM 40637H109 322,262 -12,763 -3.81 5,598 30.34 0.0199
2017-07-31 2017-06-30 13F HALOZYME THERAPEUTICS COM 40637H109 335,025 25,300 8.17 4,295 7.00 0.0171
2017-05-05 2017-03-31 13F HALOZYME THERAPEUTICS COM 40637H109 309,725 2,605 0.85 4,014 32.30 0.0176
2017-02-02 2016-12-31 13F HALOZYME THERAPEUTICS COM 40637H109 307,120 48,235 18.63 3,034 -2.97 0.0147
2016-11-04 2016-09-30 13F HALOZYME THERAPEUTICS COM 40637H109 258,885 35,605 15.95 3,127 62.27 0.0159
2016-08-11 2016-06-30 13F HALOZYME THERAPEUTICS COM 40637H109 223,280 4,515 2.06 1,927 -7.00 0.0116
2016-05-10 2016-03-31 13F/A-1 HALOZYME THERAPEUTICS COM 40637H109 218,765 5,420 2.54 2,072 -43.95 0.0129
2016-02-03 2015-12-31 13F HALOZYME THERAPEUTICS COM 40637H109 213,345 -25,046 -10.51 3,697 15.46 0.0225
2015-11-02 2015-09-30 13F/A-1 HALOZYME THERAPEUTICS COM 40637H109 238,391 133,718 127.75 3,202 35.45 0.0294
2015-10-30 2015-09-30 13F DIREXION SHS ETF TR COM 40637H109 238,391 3,203
2015-08-07 2015-06-30 13F/A-1 HALOZYME THERAPEUTICS COM 40637H109 104,673 41,460 65.59 2,364 161.79 0.0214
2015-08-04 2015-06-30 13F HALOZYME THERAPEUTICS COM 40637H109 104,673 41,460 2,364 0.0214
2015-05-14 2015-03-31 13F/A-1 HALOZYME THERAPEUTICS COM 40637H109 63,213 63,213 903 0.0078
2015-05-01 2015-03-31 13F HALOZYME THERAPEUTICS COM 40637H109 63,213 903
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.